{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:56:50Z","timestamp":1794542210233,"version":"4.9.1"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11102-026-01639-z","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:15:16Z","timestamp":1777418116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Consensus on acromegaly complications: an update"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"Andrea","family":"Giustina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6117-0081","authenticated-orcid":false,"given":"Luigi","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-6147","authenticated-orcid":false,"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-7093","authenticated-orcid":false,"given":"Susan L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-9866","authenticated-orcid":false,"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-1913","authenticated-orcid":false,"given":"Ra\u00fal M.","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-9588","authenticated-orcid":false,"given":"Ken K Y","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-7941","authenticated-orcid":false,"given":"Cesar L.","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-0126","authenticated-orcid":false,"given":"Aart Jan","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-6832","authenticated-orcid":false,"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-0679","authenticated-orcid":false,"given":"Nienke","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-6143","authenticated-orcid":false,"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"Monica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-9802","authenticated-orcid":false,"given":"Adriana G.","family":"Ioachimescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-8105","authenticated-orcid":false,"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-7357","authenticated-orcid":false,"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-140X","authenticated-orcid":false,"given":"Pinar","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-263X","authenticated-orcid":false,"given":"Pietro","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-9618","authenticated-orcid":false,"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1955-4957","authenticated-orcid":false,"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-6873","authenticated-orcid":false,"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-488X","authenticated-orcid":false,"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-0105","authenticated-orcid":false,"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-7394","authenticated-orcid":false,"given":"Ignacio","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5598","authenticated-orcid":false,"given":"Stefano","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-6691","authenticated-orcid":false,"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-6782","authenticated-orcid":false,"given":"John","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-8161","authenticated-orcid":false,"given":"Felipe F","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4049-2559","authenticated-orcid":false,"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-2281","authenticated-orcid":false,"given":"Pietro","family":"Mortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-0282","authenticated-orcid":false,"given":"Sebastian","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":false,"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-8142","authenticated-orcid":false,"given":"Meliha Melin","family":"Uygur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":false,"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"19","key":"1639_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A, Acromegaly (2025) N Engl J Med 393(19):1926\u20131939","journal-title":"N Engl J Med"},{"issue":"11","key":"1639_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10(11):804\u2013826","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1639_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM et al (2019) Acromegaly Nat Rev Dis Primers 5(1):20","journal-title":"Acromegaly Nat Rev Dis Primers"},{"issue":"1","key":"1639_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"issue":"3","key":"1639_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1210\/er.2009-0033","volume":"31","author":"M Sherlock","year":"2010","unstructured":"Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC et al (2010) Mortality in patients with pituitary disease. Endocr Rev 31(3):301\u2013342","journal-title":"Endocr Rev"},{"issue":"1","key":"1639_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322","journal-title":"Pituitary"},{"issue":"11","key":"1639_CR7","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr., Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1639_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1639_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/BF03349263","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31(9):820\u2013838","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1639_CR10","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/BF03349164","volume":"26","author":"A Giustina","year":"2003","unstructured":"Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA et al (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26(12):1242\u20131247","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1639_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1639_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294\u2013302","journal-title":"Pituitary"},{"key":"1639_CR13","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):e937\u2013e946","DOI":"10.1210\/clinem\/dgz096"},{"issue":"5","key":"1639_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS et al (2017) Criteria for the definition of pituitary tumor centers of excellence (PTCOE): A pituitary society statement. Pituitary 20(5):489\u2013498","journal-title":"Pituitary"},{"issue":"4","key":"1639_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al (2024) Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary 27(4):381\u2013388","journal-title":"Pituitary"},{"issue":"7650","key":"1639_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"3","key":"1639_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo BA, Murad MH, Sch\u00fcnemann HJ, Kunz R, Vigersky RA, Guyatt GH et al (2008) A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93(3):666\u2013673","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1639_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tem.2016.02.005","volume":"27","author":"NC Olarescu","year":"2016","unstructured":"Olarescu NC, Bollerslev J (2016) The impact of adipose tissue on insulin resistance in acromegaly. Trends Endocrinol Metab 27(4):226\u2013237","journal-title":"Trends Endocrinol Metab"},{"key":"1639_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fendo.2019.00509","volume":"10","author":"G Vila","year":"2019","unstructured":"Vila G, J\u00f8rgensen JOL, Luger A, Stalla GK (2019) Insulin resistance in patients with acromegaly. Front Endocrinol (Lausanne) 10:509","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1639_CR20","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1210\/en.2008-0143","volume":"149","author":"P Kamenicky","year":"2008","unstructured":"Kamenicky P, Viengchareun S, Blanchard A, Meduri G, Zizzari P, Imbert-Teboul M et al (2008) Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149(7):3294\u20133305","journal-title":"Endocrinology"},{"issue":"3","key":"1639_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2265.1992.tb01443.x","volume":"36","author":"KK Ho","year":"1992","unstructured":"Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36(3):271\u2013279","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1639_CR22","first-page":"193","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P et al (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85(1):193\u2013199","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR23","first-page":"381","volume":"78","author":"AJ O\u2019Sullivan","year":"1994","unstructured":"O\u2019Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK (1994) Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 78(2):381\u2013386","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/er.2013-1071","volume":"35","author":"P Kamenick\u00fd","year":"2014","unstructured":"Kamenick\u00fd P, Mazziotti G, Lomb\u00e8s M, Giustina A, Chanson P (2014) Growth Hormone, Insulin-Like growth Factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35(2):234\u2013281","journal-title":"Endocr Rev"},{"issue":"2","key":"1639_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1210\/jcem-35-2-194","volume":"35","author":"LE UNDERWOOD","year":"1972","unstructured":"UNDERWOOD LE, HINTZ RL, VOINA SJ, VAN WYK JJ (1972) Human Somatomedin, the growth Hormone-Dependent sulfation Factor, is Anti-Lipolytic. J Clin Endocrinol Metabolism 35(2):194\u2013198","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1639_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","volume":"16","author":"JJ Kopchick","year":"2020","unstructured":"Kopchick JJ, Berryman DE, Puri V, Lee KY, Jorgensen JOL (2020) The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nat Rev Endocrinol 16(3):135\u2013146","journal-title":"Nat Rev Endocrinol"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/978-1-59259-712-3_24","volume-title":"The IGF system: molecular Biology, Physiology, and clinical applications","author":"J Zapf","year":"1999","unstructured":"Zapf J, Froesch ER, Schmid C (1999) Metabolic effects of IGFs. In: Rosenfeld RG, Roberts CT (eds) The IGF system: molecular Biology, Physiology, and clinical applications. Humana, Totowa, NJ, pp 577\u2013616"},{"issue":"2","key":"1639_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12020-018-1797-8","volume":"63","author":"C Briet","year":"2019","unstructured":"Briet C, Ilie MD, Kuhn E, Maione L, Brailly-Tabard S, Salenave S et al (2019) Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature. Endocrine 63(2):348\u2013360","journal-title":"Endocrine"},{"issue":"7","key":"1639_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27(7):470\u2013483","journal-title":"Trends Endocrinol Metab"},{"issue":"35","key":"1639_CR30","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.2174\/1381612825666191106091507","volume":"25","author":"M Obradovic","year":"2019","unstructured":"Obradovic M, Zafirovic S, Soskic S, Stanimirovic J, Trpkovic A, Jevremovic D et al (2019) Effects of IGF-1 on the cardiovascular system. Curr Pharm Des 25(35):3715\u20133725","journal-title":"Curr Pharm Des"},{"issue":"9","key":"1639_CR31","doi-asserted-by":"publisher","first-page":"e37279","DOI":"10.1097\/MD.0000000000037279","volume":"103","author":"Z Yan","year":"2024","unstructured":"Yan Z, Xing Z, Xue T, Zhao J, Li G, Xu L et al (2024) Insulin-like growth factor-1 in myocardial ischemia-reperfusion injury: A review. Med (Baltim) 103(9):e37279","journal-title":"Med (Baltim)"},{"key":"1639_CR32","doi-asserted-by":"publisher","first-page":"1142644","DOI":"10.3389\/fendo.2023.1142644","volume":"14","author":"M Macvanin","year":"2023","unstructured":"Macvanin M, Gluvic Z, Radovanovic J, Essack M, Gao X, Isenovic ER (2023) New insights on the cardiovascular effects of IGF-1. Front Endocrinol (Lausanne) 14:1142644","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1639_CR33","doi-asserted-by":"publisher","first-page":"T115","DOI":"10.1530\/JME-17-0298","volume":"61","author":"S Yakar","year":"2018","unstructured":"Yakar S, Werner H, Rosen CJ (2018) Insulin-like growth factors: actions on the skeleton. J Mol Endocrinol 61(1):T115\u2013t37","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"1639_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/biom11040531","volume":"11","author":"H Werner","year":"2021","unstructured":"Werner H, Sarfstein R, Laron Z (2021) The role of nuclear insulin and IGF1 receptors in metabolism and cancer. Biomolecules 11(4):531","journal-title":"Biomolecules"},{"issue":"6","key":"1639_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s11102-024-01468-y","volume":"27","author":"S Frara","year":"2024","unstructured":"Frara S, Acanfora M, Franzese V, Brandi ML, Losa M, Giustina A (2024) Novel approach to bone comorbidity in resistant acromegaly. Pituitary 27(6):813\u2013823","journal-title":"Pituitary"},{"issue":"6","key":"1639_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11102-024-01464-2","volume":"27","author":"S Bolamperti","year":"2024","unstructured":"Bolamperti S, Villa I, di Filippo L (2024) Growth hormone and bone: a basic perspective. Pituitary 27(6):745\u2013751","journal-title":"Pituitary"},{"issue":"1","key":"1639_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59\u201371","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1639_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11154-024-09875-z","volume":"25","author":"C Rosendal","year":"2024","unstructured":"Rosendal C, Arlien-S\u00f8borg MC, Nielsen EH, Andersen MS, Feltoft CL, Kistorp C et al (2024) The changing landscape of acromegaly \u2013 an epidemiological perspective. Reviews Endocr Metabolic Disorders 25(4):691\u2013705","journal-title":"Reviews Endocr Metabolic Disorders"},{"issue":"6","key":"1639_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/cen.15060","volume":"100","author":"S Orme","year":"2024","unstructured":"Orme S, McNally R, James PW, Davis J, Ayuk J, Higham C et al (2024) Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK acromegaly register 1970\u20132016. Clin Endocrinol (Oxf) 100(6):558\u2013564","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"1639_CR40","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","volume":"108","author":"B Biagetti","year":"2023","unstructured":"Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M et al (2023) Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general Spanish population. J Clin Endocrinol Metab 108(9):2193\u20132202","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/EJE-16-1064","volume":"176","author":"L Maione","year":"2017","unstructured":"Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F et al (2017) Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol 176(5):645\u2013655","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1639_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/ERC-16-0106","volume":"23","author":"E Ritvonen","year":"2016","unstructured":"Ritvonen E, L\u00f6yttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P et al (2016) Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer 23(6):469\u2013480","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1639_CR43","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E et al (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438\u20134446","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11102-024-01432-w","volume":"27","author":"LM Del Corso","year":"2024","unstructured":"Del Corso LM, Mesa Junior CO, Andrade VFC, Fidalski SZK, Boguszewski CL (2024) Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis. Pituitary 27(5):537\u2013544","journal-title":"Pituitary"},{"issue":"4","key":"1639_CR45","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ecl.2019.08.008","volume":"48","author":"S Puglisi","year":"2019","unstructured":"Puglisi S, Terzolo M (2019) Hypertension and acromegaly. Endocrinol Metab Clin North Am 48(4):779\u2013793","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"15","key":"1639_CR46","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","volume":"43","author":"S Hong","year":"2022","unstructured":"Hong S, Kim KS, Han K, Park CY (2022) Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 43(15):1491\u20131499","journal-title":"Eur Heart J"},{"issue":"6","key":"1639_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11102-025-01586-1","volume":"28","author":"M Araujo-Castro","year":"2025","unstructured":"Araujo-Castro M, Garc\u00eda-Centeno R, Gonz\u00e1lez L, Lacerda Nobre E, de Grin\u00e9 Severino M, Goi J et al (2025) Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly. Pituitary 28(6):119","journal-title":"Pituitary"},{"issue":"5","key":"1639_CR48","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/EJE-16-0562","volume":"175","author":"C Sardella","year":"2016","unstructured":"Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L et al (2016) Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol 175(5):443\u2013453","journal-title":"Eur J Endocrinol"},{"key":"1639_CR49","doi-asserted-by":"publisher","first-page":"577173","DOI":"10.3389\/fendo.2020.577173","volume":"11","author":"G Vila","year":"2020","unstructured":"Vila G, Luger A, van der Lely AJ, Neggers S, Webb SM, Biller BMK et al (2020) Hypertension in acromegaly in relationship to biochemical control and mortality: global ACROSTUDY outcomes. Front Endocrinol (Lausanne) 11:577173","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1639_CR50","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1210\/jc.2018-00325","volume":"103","author":"B Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez B, Vargas G, de Los Monteros ALE, Mendoza V, Mercado M (2018) Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab 103(6):2369\u20132375","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1639_CR51","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11102-023-01321-8","volume":"26","author":"P Rocha","year":"2023","unstructured":"Rocha P, Barroso J, Carlos F, Muxfeldt E, Gadelha M, Kasuki L (2023) Importance of 24\u00a0h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings. Pituitary 26(4):402\u2013410","journal-title":"Pituitary"},{"key":"1639_CR52","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al (2025) AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82(10):e212-e316"},{"issue":"7","key":"1639_CR53","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1210\/jc.2011-0078","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky P, Blanchard A, Frank M, Salenave S, Letierce A, Azizi M et al (2011) Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metabolism 96(7):2127\u20132135","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"7","key":"1639_CR54","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1210\/jc.2008-0299","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M et al (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metabolism 93(7):2639\u20132646","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1639_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","volume":"55","author":"G Minniti","year":"2001","unstructured":"Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C et al (2001) Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55(3):307\u2013313","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1639_CR56","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1210\/jc.2014-2259","volume":"99","author":"C Reyes-Vidal","year":"2014","unstructured":"Reyes-Vidal C, Fernandez JC, Bruce JN, Crisman C, Conwell IM, Kostadinov J et al (2014) Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 99(11):4124\u20134132","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/jc.2003-030915","volume":"89","author":"O Serri","year":"2004","unstructured":"Serri O, Beauregard C, Hardy J (2004) Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 89(2):658\u2013661","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1639_CR58","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and Insulin-Like growth Factor-I Levels, tumor Shrinkage, and cardiovascular disease: A prospective study. J Clin Endocrinol Metabolism 94(10):3746\u20133756","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"1639_CR59","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1210\/jc.2006-2547","volume":"92","author":"P Maison","year":"2007","unstructured":"Maison P, Tropeano A-I, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: A metaanalysis. J Clin Endocrinol Metabolism 92(5):1743\u20131747","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1639_CR60","doi-asserted-by":"crossref","unstructured":"Ramos-Lev\u00ed AM, Marazuela M (2019) Bringing cardiovascular comorbidities in acromegaly to an Update. How should we diagnose and manage them? Front Endocrinol 10:120","DOI":"10.3389\/fendo.2019.00120"},{"issue":"12","key":"1639_CR61","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.eprac.2024.09.014","volume":"30","author":"RPV Sherin","year":"2024","unstructured":"Sherin RPV, Vietor NO, Usman A, Hoang TD, Shakir MKM (2024) Cardiovascular disorders associated with acromegaly: an update. Endocr Pract 30(12):1212\u20131219","journal-title":"Endocr Pract"},{"issue":"1","key":"1639_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102\u2013152","journal-title":"Endocr Rev"},{"key":"1639_CR63","doi-asserted-by":"publisher","first-page":"1260842","DOI":"10.3389\/fendo.2023.1260842","volume":"14","author":"R Huang","year":"2023","unstructured":"Huang R, Jin J, Zhang P, Yan K, Zhang H, Chen X et al (2023) Use of speckle tracking echocardiography in evaluating cardiac dysfunction in patients with acromegaly: an update. Front Endocrinol (Lausanne) 14:1260842","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1639_CR64","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2015-2675","volume":"100","author":"CM dos Santos Silva","year":"2015","unstructured":"dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA et al (2015) Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab 100(12):4447\u20134455","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1639_CR65","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11102-024-01403-1","volume":"27","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D, Feola T, Cozzolino A, Pofi R, Galea N, Catalano C et al (2024) The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study. Pituitary 27(4):416\u2013427","journal-title":"Pituitary"},{"issue":"4","key":"1639_CR66","first-page":"1551","volume":"86","author":"A Colao","year":"2001","unstructured":"Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM et al (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86(4):1551\u20131557","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1530\/EJE-15-0500","volume":"173","author":"E Kuhn","year":"2015","unstructured":"Kuhn E, Maione L, Bouchachi A, Rozi\u00e8re M, Salenave S, Brailly-Tabard S et al (2015) Long-term effects of Pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol 173(5):693\u2013702","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1639_CR68","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1210\/jc.2004-0821","volume":"89","author":"H Bihan","year":"2004","unstructured":"Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S et al (2004) Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89(11):5308\u20135313","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR69","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12020-016-1191-3","volume":"55","author":"AM Ramos-Lev\u00ed","year":"2017","unstructured":"Ramos-Lev\u00ed AM, Marazuela M (2017) Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 55(2):346\u2013359","journal-title":"Endocrine"},{"issue":"6","key":"1639_CR70","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","volume":"19","author":"L Warszawski","year":"2016","unstructured":"Warszawski L, Kasuki L, S\u00e1 R, Dos Santos Silva CM, Volschan I, Gottlieb I et al (2016) Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19(6):582\u2013589","journal-title":"Pituitary"},{"issue":"2","key":"1639_CR71","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-012-9828-3","volume":"43","author":"M Unubol","year":"2013","unstructured":"Unubol M, Eryilmaz U, Guney E, Ture M, Akgullu C (2013) QT dispersion in patients with acromegaly. Endocrine 43(2):419\u2013423","journal-title":"Endocrine"},{"issue":"2","key":"1639_CR72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijcard.2004.12.010","volume":"104","author":"P Maffei","year":"2005","unstructured":"Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E et al (2005) Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol 104(2):197\u2013203","journal-title":"Int J Cardiol"},{"issue":"4","key":"1639_CR73","doi-asserted-by":"publisher","first-page":"e0125639","DOI":"10.1371\/journal.pone.0125639","volume":"10","author":"A Orosz","year":"2015","unstructured":"Orosz A, Csajb\u00f3k \u00c9, Cz\u00e9kus C, Gavall\u00e9r H, Magony S, Valkusz Z et al (2015) Increased Short-Term Beat-To-Beat variability of QT interval in patients with acromegaly. PLoS ONE 10(4):e0125639","journal-title":"PLoS ONE"},{"issue":"1","key":"1639_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jcph.213","volume":"54","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Darstein C, Ligueros-Saylan M, Jordaan P, Song D et al (2014) Effects of subcutaneous Pasireotide on cardiac repolarization in healthy volunteers: a Single-Center, phase I, Randomized, Four\u2010Way crossover study. J Clin Pharmacol 54(1):75\u201386","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1639_CR75","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","volume":"17","author":"J MacKenzie Feder","year":"2014","unstructured":"MacKenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2014) Pasireotide monotherapy in cushing\u2019s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary 17(6):519\u2013529","journal-title":"Pituitary"},{"key":"1639_CR76","unstructured":"Drugs@FDA: FDA approved drug products. Pasireotide (2018). Accessed 1 May . https:\/\/www.accessdata.fda.gov\/"},{"issue":"2","key":"1639_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40618-020-01343-0","volume":"44","author":"M Parolin","year":"2021","unstructured":"Parolin M, Dassie F, Vettor R, Steeds RP, Maffei P (2021) Electrophysiological features in acromegaly: re-thinking the arrhythmic risk? J Endocrinol Investig 44(2):209\u2013221","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"1639_CR78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/EJE-12-0596","volume":"168","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M et al (2013) Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 168(1):15\u201322","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1639_CR79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M, Kristensen L, Laurberg P, Pedersen L et al (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol 175(3):181\u2013190","journal-title":"Eur J Endocrinol"},{"issue":"3\u20134","key":"1639_CR80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000095530","volume":"83","author":"G Lombardi","year":"2006","unstructured":"Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3\u20134):211\u2013217","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1639_CR81","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R et al (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20(1):46\u201362","journal-title":"Pituitary"},{"key":"1639_CR82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.sleep.2021.01.033","volume":"80","author":"W Cao","year":"2021","unstructured":"Cao W, Wang X, Luo J, Huang R, Xiao Y (2021) Impact of obstructive sleep apnea on cardiovascular risk in patients with acromegaly. Sleep Med 80:193\u2013198","journal-title":"Sleep Med"},{"issue":"6","key":"1639_CR83","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s11325-023-02838-9","volume":"27","author":"I Filchenko","year":"2023","unstructured":"Filchenko I, Korostovtseva L, Bochkarev M, Tsoy U, Sviryaev Y (2023) Cardiovascular remodeling in active and controlled acromegaly: association with sleep-disordered breathing. Sleep Breath 27(6):2305\u20132314","journal-title":"Sleep Breath"},{"issue":"3","key":"1639_CR84","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12020-019-02061-1","volume":"66","author":"A Wennberg","year":"2019","unstructured":"Wennberg A, Lorusso R, Dassie F, Benavides-Varela S, Parolin M, De Carlo E et al (2019) Sleep disorders and cognitive dysfunction in acromegaly. Endocrine 66(3):634\u2013641","journal-title":"Endocrine"},{"issue":"3","key":"1639_CR85","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1210\/jc.2012-3072","volume":"98","author":"AK Annamalai","year":"2013","unstructured":"Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F et al (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040\u20131050","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1530\/EJE-09-0694","volume":"161","author":"C Berg","year":"2009","unstructured":"Berg C, Wessendorf TE, Mortsch F, Forsting M, Teschler H, Weischer T et al (2009) Influence of disease control with Pegvisomant on sleep Apnoea and tongue volume in patients with active acromegaly. Eur J Endocrinol 161(6):829\u2013835","journal-title":"Eur J Endocrinol"},{"key":"1639_CR87","doi-asserted-by":"crossref","unstructured":"Parolin M, Dassie F, Alessio L, Wennberg A, Rossato M, Vettor R et al (2020) Obstructive sleep apnea in acromegaly and the effect of treatment: A systematic review and Meta-Analysis. J Clin Endocrinol Metab 105(3):e23\u2013e31","DOI":"10.1210\/clinem\/dgz116"},{"issue":"4","key":"1639_CR88","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3803\/EnM.2024.1933","volume":"39","author":"J Cho","year":"2024","unstructured":"Cho J, Kim JH, Kim YH, Lee J (2024) Obstructive sleep apnea screening and effects of surgery in acromegaly: A prospective study. Endocrinol Metab (Seoul) 39(4):641\u2013652","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"1639_CR89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1210\/clinem\/dgz050","volume":"105","author":"TLC Wolters","year":"2020","unstructured":"Wolters TLC, Roerink S, Drenthen LCA, van Haren-Willems J, Wagenmakers M, Smit JWA et al (2020) The course of obstructive sleep apnea syndrome in patients with acromegaly during treatment. J Clin Endocrinol Metab 105(1):290\u2013304","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1639_CR90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cen.14994","volume":"100","author":"AS Powlson","year":"2024","unstructured":"Powlson AS, Annamalai AK, Moir S, Webb AJ, Bala L, Graggaber J et al (2024) High prevalence of severe sleep cycle disruption in de Novo acromegaly and underdiagnosis by common clinical screening tools: A prospective, observational, cross-sectional study. Clin Endocrinol (Oxf) 100(3):251\u2013259","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1639_CR91","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1210\/jc.2013-4288","volume":"99","author":"D Chemla","year":"2014","unstructured":"Chemla D, Attal P, Maione L, Veyer AS, Mroue G, Baud D et al (2014) Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea. J Clin Endocrinol Metab 99(8):2925\u20132931","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR92","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-08-0442","volume":"159","author":"MV Davi","year":"2008","unstructured":"Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V et al (2008) Sleep Apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159(5):533\u2013540","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1639_CR93","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1210\/er.2003-0009","volume":"24","author":"RN Clayton","year":"2003","unstructured":"Clayton RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24(3):272\u2013277","journal-title":"Endocr Rev"},{"issue":"5","key":"1639_CR94","first-page":"1518","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte AMD et al (1999) Impact of patient\u2019s age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J Clin Endocrinol Metabolism 84(5):1518\u20131523","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"9","key":"1639_CR95","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1210\/jc.2003-030462","volume":"88","author":"L Spinelli","year":"2003","unstructured":"Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A et al (2003) Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J Clin Endocrinol Metabolism 88(9):4105\u20134109","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1639_CR96","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1210\/er.2004-0022","volume":"27","author":"LJ Woodhouse","year":"2006","unstructured":"Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S (2006) The influence of growth hormone status on physical Impairments, functional Limitations, and Health-Related quality of life in adults. Endocr Rev 27(3):287\u2013317","journal-title":"Endocr Rev"},{"issue":"15","key":"1639_CR97","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042\u20131047","journal-title":"Am J Cardiol"},{"issue":"2","key":"1639_CR98","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","volume":"58","author":"A Colao","year":"2003","unstructured":"Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D et al (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58(2):169\u2013176","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1639_CR99","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1530\/eje.0.1340554","volume":"134","author":"SJ Padayatty","year":"1996","unstructured":"Padayatty SJ, Perrins EJ, Belchetz PE (1996) Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 134(5):554\u2013559","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1639_CR100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1046\/j.1365-2265.2002.01476.x","volume":"56","author":"SG Thomas","year":"2002","unstructured":"Thomas SG, Woodhouse LJ, Pagura SM, Ezzat S (2002) Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol (Oxf) 56(3):351\u2013358","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1639_CR101","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/cen.12708","volume":"83","author":"E Hatipoglu","year":"2015","unstructured":"Hatipoglu E, Topsakal N, Erkut Atilgan O, Camliguney AF, Ikitimur B, Ugurlu S et al (2015) Physical and cardiovascular performance in cases with acromegaly after regular short-term exercise. Clin Endocrinol (Oxf) 83(1):91\u201397","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1639_CR102","doi-asserted-by":"publisher","first-page":"bvae032","DOI":"10.1210\/jendso\/bvae032","volume":"8","author":"A Milioto","year":"2024","unstructured":"Milioto A, Corica G, Nista F, Wildemberg LEA, Rossi F, Bignotti B et al (2024) Skeletal muscle evaluation in patients with acromegaly. J Endocr Soc 8(4):bvae032","journal-title":"J Endocr Soc"},{"issue":"1","key":"1639_CR103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11102-024-01494-w","volume":"28","author":"CPS Rocha","year":"2025","unstructured":"Rocha CPS, Hupalowski NN, Andrade VFC, Boguszewski CL, Borba VZC (2025) Assessment of sarcopenic obesity in patients with acromegaly. Pituitary 28(1):25","journal-title":"Pituitary"},{"issue":"10","key":"1639_CR104","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M et al (2017) Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge acromegaly survey (LAS) database. Endocr Relat Cancer 24(10):505\u2013518","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1639_CR105","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","volume":"26","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML (2023) Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4):319\u2013332","journal-title":"Pituitary"},{"issue":"6","key":"1639_CR106","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ando.2024.09.002","volume":"85","author":"G Fauchier","year":"2024","unstructured":"Fauchier G, Laurent E, Maione L, Lecuyer AI, Herbert J, Pierre-Renoult P et al (2024) Acromegaly: Incidence, patient characteristics and treatment patterns in a 10-year nationwide retrospective hospital cohort study. Ann Endocrinol (Paris) 85(6):589\u2013595","journal-title":"Ann Endocrinol (Paris)"},{"issue":"9","key":"1639_CR107","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","volume":"20","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, J\u00f8rgensen JOL et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 20(9):541\u2013552","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1639_CR108","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"Esposito D, Olsson DS, Franz\u00e9n S, Miftaraj M, N\u00e5tman J, Gudbj\u00f6rnsdottir S et al (2022) Effect of diabetes on morbidity and mortality in patients with acromegaly. J Clin Endocrinol Metab 107(9):2483\u20132492","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement1","key":"1639_CR109","first-page":"S128","volume":"48","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP (2024) 6. Glycemic goals and hypoglycemia: standards of care in Diabetes\u20142025. Diabetes Care 48(Supplement1):S128\u2013S45","journal-title":"Diabetes Care"},{"issue":"1","key":"1639_CR110","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11102-024-01477-x","volume":"28","author":"B Biagetti","year":"2024","unstructured":"Biagetti B, Araujo-Castro M, Marazuela M, Puig-Domingo M (2024) Treatment of acromegaly-induced diabetes: an updated proposal. Pituitary 28(1):15","journal-title":"Pituitary"},{"issue":"6","key":"1639_CR111","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1530\/EJE-20-0497","volume":"183","author":"A Cozzolino","year":"2020","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Hasenmajer V, Minnetti M et al (2020) Metabolic complications in acromegaly after neurosurgery: a meta-analysis. Eur J Endocrinol 183(6):597\u2013606","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1639_CR112","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/EJE-10-1096","volume":"164","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K et al (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol 164(4):467\u2013473","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1639_CR113","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11102-024-01415-x","volume":"27","author":"E Pascual-Corrales","year":"2024","unstructured":"Pascual-Corrales E, Biagetti B, Marazuela M, Asensio-Wandosel D, Rodr\u00edguez Berrocal V, Irigaray Echarri A et al (2024) Glucose metabolism outcomes after pituitary surgery in patients with acromegaly. Pituitary 27(5):497\u2013506","journal-title":"Pituitary"},{"issue":"5","key":"1639_CR114","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies. J Clin Endocrinol Metabolism 94(5):1500\u20131508","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1639_CR115","doi-asserted-by":"crossref","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E et al (2018) Somatostatin analogs and glucose metabolism in acromegaly: A Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 103(6):2089\u20132099","DOI":"10.1210\/jc.2017-02566"},{"issue":"1","key":"1639_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","volume":"26","author":"B Biagetti","year":"2025","unstructured":"Biagetti B, Araujo-Castro M, Tebe C, Marazuela M, Puig-Domingo M (2025) Real-world evidence of effectiveness and safety of Pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Rev Endocr Metab Disord 26(1):97\u2013111","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"1639_CR117","doi-asserted-by":"publisher","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","volume":"108","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X et al (2023) Long-term efficacy and safety of Pasireotide in patients with acromegaly: 14 years of Single-Center Real-World experience. J Clin Endocrinol Metab 108(12):e1571\u2013e9","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR118","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24(6):887\u2013903","journal-title":"Pituitary"},{"issue":"12","key":"1639_CR119","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190","journal-title":"Endocr Connect"},{"key":"1639_CR120","doi-asserted-by":"publisher","first-page":"1250822","DOI":"10.3389\/fendo.2024.1250822","volume":"15","author":"U Feldt-Rasmussen","year":"2024","unstructured":"Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P et al (2024) Predictive factors and the management of hyperglycemia in patients with acromegaly and cushing\u2019s disease receiving Pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol (Lausanne) 15:1250822","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1639_CR121","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M et al (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study. Eur J Endocrinol 182(6):583","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1639_CR122","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E et al (2019) Pegvisomant improves glucose metabolism in acromegaly: A Meta-Analysis of prospective interventional studies. J Clin Endocrinol Metab 104(7):2892\u20132902","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement1","key":"1639_CR123","first-page":"S181","volume":"48","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142025. Diabetes Care 48(Supplement1):S181\u2013S206","journal-title":"Diabetes Care"},{"issue":"5","key":"1639_CR124","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1210\/jc.2017-00082","volume":"102","author":"M Quarella","year":"2017","unstructured":"Quarella M, Walser D, Br\u00e4ndle M, Fournier J-Y, Bilz S (2017) Rapid onset of diabetic ketoacidosis after SGLT2 Inhibition in a patient with unrecognized acromegaly. J Clin Endocrinol Metabolism 102(5):1451\u20131453","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"1639_CR125","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.tem.2018.11.007","volume":"30","author":"Z Adnan","year":"2019","unstructured":"Adnan Z (2019) Sodium glucose Co-transporter inhibitors in patients with acromegaly and diabetes. Trends Endocrinol Metabolism 30(2):77\u201379","journal-title":"Trends Endocrinol Metabolism"},{"key":"1639_CR126","doi-asserted-by":"crossref","unstructured":"Jensen MH, Gasbjerg LS, Skov-Jeppesen K, Jacobsen JCB, Poulsen SS, Zhou C et al (2024) GIP receptor antagonism eliminates Paradoxical growth hormone secretion in some patients with acromegaly. J Clin Endocrinol Metab 110(3):715\u2013729","DOI":"10.1210\/clinem\/dgae583"},{"issue":"4","key":"1639_CR127","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1210\/clinem\/dgaa014","volume":"105","author":"M Wang","year":"2020","unstructured":"Wang M, Guo S, He M, Shao X, Feng L, Yu Y et al (2020) High-Performance liquid Chromatography-Mass Spectrometry-Based lipid metabolite profiling of acromegaly. J Clin Endocrinol Metabolism 105(4):e1075\u2013e84","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1639_CR128","doi-asserted-by":"publisher","first-page":"101667","DOI":"10.1016\/j.beem.2022.101667","volume":"37","author":"CB Newman","year":"2023","unstructured":"Newman CB (2023) Effects of endocrine disorders on lipids and lipoproteins. Best Pract Res Clin Endocrinol Metab 37(3):101667","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"1639_CR129","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11892-018-1101-6","volume":"18","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Eckel RH (2018) Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep 18(12):127","journal-title":"Curr Diab Rep"},{"issue":"1","key":"1639_CR130","first-page":"24","volume":"65","author":"VB Chueire","year":"2021","unstructured":"Chueire VB, Muscelli E (2021) Effect of free fatty acids on insulin secretion, insulin sensitivity and incretin effect - a narrative review. Arch Endocrinol Metab 65(1):24\u201331","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"1639_CR131","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JOL (2009) Effects of growth hormone on Glucose, Lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152\u2013177","journal-title":"Endocr Rev"},{"issue":"1","key":"1639_CR132","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1055\/a-1717-9332","volume":"54","author":"XQ Shao","year":"2022","unstructured":"Shao XQ, Chen ZY, Wang M, Yang YP, Yu YF, Liu WJ et al (2022) Effects of Long-Acting somatostatin analogues on lipid metabolism in patients with newly diagnosed acromegaly: A retrospective study of 120 cases. Horm Metab Res 54(1):25\u201332","journal-title":"Horm Metab Res"},{"issue":"4","key":"1639_CR133","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/cen.13285","volume":"86","author":"PJ Caron","year":"2017","unstructured":"Caron PJ, Petersenn S, Houchard A, Sert C, Bevan JS (2017) Glucose and lipid levels with Lanreotide autogel 120\u00a0mg in treatment-na\u00efve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf) 86(4):541\u2013551","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1639_CR134","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","volume":"31","author":"SB Patel","year":"2025","unstructured":"Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S et al (2025) American association of clinical endocrinology clinical practice guideline on Pharmacologic management of adults with dyslipidemia. Endocr Pract 31(2):236\u2013262","journal-title":"Endocr Pract"},{"issue":"1","key":"1639_CR135","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"key":"1639_CR136","doi-asserted-by":"crossref","unstructured":"Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG et al (2020) Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 105(12):3613\u20133682","DOI":"10.1210\/clinem\/dgaa674"},{"issue":"10","key":"1639_CR137","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1210\/clinem\/dgad206","volume":"108","author":"P Fellinger","year":"2023","unstructured":"Fellinger P, Beiglb\u00f6ck H, Semmler G, Pfleger L, Smajis S, Baumgartner C et al (2023) Increased GH\/IGF-I axis activity relates to lower hepatic lipids and phosphor metabolism. J Clin Endocrinol Metab 108(10):e989\u2013e97","journal-title":"J Clin Endocrinol Metab"},{"key":"1639_CR138","doi-asserted-by":"crossref","unstructured":"Fellinger P, Wolf P, Pfleger L, Krumpolec P, Krssak M, Klavins K et al (2020) Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight 5(5)","DOI":"10.1172\/jci.insight.134638"},{"issue":"7","key":"1639_CR139","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40618-022-01775-w","volume":"45","author":"MM Uygur","year":"2022","unstructured":"Uygur MM, Dereli Yaz\u0131c\u0131 D, Gogas Yavuz D (2022) Low serm fibroblast growth Factor-21 levels is not associated with carotid intima-media thickness in acromegaly patients. J Endocrinol Invest 45(7):1405\u20131412","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1639_CR140","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1210\/clinem\/dgad490","volume":"109","author":"\u0130 Ero\u011flu","year":"2023","unstructured":"Ero\u011flu \u0130, Iremli BG, Idilman IS, Yuce D, Lay I, Akata D et al (2023) Nonalcoholic fatty liver Disease, liver Fibrosis, and utility of noninvasive scores in patients with acromegaly. J Clin Endocrinol Metab 109(1):e119\u2013e29","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1639_CR141","doi-asserted-by":"publisher","first-page":"e00090","DOI":"10.1002\/edm2.90","volume":"2","author":"A Koutsou-Tassopoulou","year":"2019","unstructured":"Koutsou-Tassopoulou A, Papapostoli\u2010Sklavounou I, Krawczyk M, Friesenhahn\u2010Ochs B, Weber SN, Lammert F et al (2019) Hepatic steatosis in patients with acromegaly. Endocrinol Diabetes Metabolism 2(4):e00090","journal-title":"Endocrinol Diabetes Metabolism"},{"issue":"4","key":"1639_CR142","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/jc.2011-2681","volume":"97","author":"M Madsen","year":"2012","unstructured":"Madsen M, Krusenstjerna-Hafstr\u00f8m T, M\u00f8ller L, Christensen B, Vendelbo MH, Pedersen SB et al (2012) Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab 97(4):1227\u20131235","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR143","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","volume":"79","author":"AL Hutchison","year":"2023","unstructured":"Hutchison AL, Tavaglione F, Romeo S, Charlton M (2023) Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol 79(6):1524\u20131541","journal-title":"J Hepatol"},{"issue":"1","key":"1639_CR144","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/EJE-12-0252","volume":"167","author":"H Nishizawa","year":"2012","unstructured":"Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H et al (2012) Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 167(1):67\u201374","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1639_CR145","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835","journal-title":"Hepatology"},{"issue":"6","key":"1639_CR146","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2007-2780","volume":"93","author":"PU Freda","year":"2008","unstructured":"Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN et al (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93(6):2334\u20132343","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1639_CR147","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s40618-025-02624-2","volume":"48","author":"AC Inojosa","year":"2025","unstructured":"Inojosa AC, Hirt AV, Ara\u00fajo T, Ferreira ME, Andrade L, Cunha V et al (2025) Sarcopenic obesity and physical function in acromegaly: impact of disease control and evaluation using dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis. J Endocrinol Investig 48(9):2027\u20132039","journal-title":"J Endocrinol Investig"},{"issue":"8","key":"1639_CR148","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC et al (2015) Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 100(8):2946\u20132955","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1639_CR149","doi-asserted-by":"publisher","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","volume":"5","author":"AP Kuker","year":"2021","unstructured":"Kuker AP, Shen W, Jin Z, Singh S, Chen J, Bruce JN et al (2021) Body composition changes with Long-term Pegvisomant therapy of acromegaly. J Endocr Soc 5(3):bvab004","journal-title":"J Endocr Soc"},{"issue":"8","key":"1639_CR150","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1210\/jc.2009-0026","volume":"94","author":"PU Freda","year":"2009","unstructured":"Freda PU, Shen W, Reyes-Vidal CM, Geer EB, Arias-Mendoza F, Gallagher D et al (2009) Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry. J Clin Endocrinol Metab 94(8):2880\u20132886","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR151","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"Giustina A, Mazziotti G, Canalis E (2008) Growth Hormone, Insulin-Like growth Factors, and the skeleton. Endocr Rev 29(5):535\u2013559","journal-title":"Endocr Rev"},{"issue":"4","key":"1639_CR152","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","volume":"34","author":"MM Uygur","year":"2023","unstructured":"Uygur MM, Frara S, di Filippo L, Giustina A (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab 34(4):231\u2013242","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"1639_CR153","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440\u2013488","journal-title":"Endocr Rev"},{"issue":"12","key":"1639_CR154","first-page":"e5088","volume":"106","author":"M Ku\u017ema","year":"2021","unstructured":"Ku\u017ema M, Va\u0148uga P, S\u00e1gov\u00e1 I, P\u00e1vai D, Jackuliak P, Killinger Z et al (2021) Vertebral fractures occur despite control of acromegaly and are predicted by cortical volumetric bone mineral density. J Clin Endocrinol Metab 106(12):e5088\u2013e96","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR155","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3803\/EnM.2023.1782","volume":"38","author":"J Kim","year":"2023","unstructured":"Kim J, Hong N, Choi J, Moon JH, Kim EH, Lee EJ et al (2023) Increased risk of hip fracture in patients with acromegaly: A nationwide cohort study in Korea. Endocrinol Metab (Seoul) 38(6):690\u2013700","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9","key":"1639_CR156","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-023-06800-z","volume":"34","author":"H Kwon","year":"2023","unstructured":"Kwon H, Han KD, Kim BS, Moon SJ, Park SE, Rhee EJ et al (2023) Acromegaly and the long-term fracture risk of the vertebra and hip: a National cohort study. Osteoporos Int 34(9):1591\u20131600","journal-title":"Osteoporos Int"},{"key":"1639_CR157","doi-asserted-by":"publisher","first-page":"1448566","DOI":"10.3389\/fendo.2024.1448566","volume":"15","author":"M Ku\u017ema","year":"2024","unstructured":"Ku\u017ema M, Va\u0148uga P, P\u00e1vai D, Killinger Z, Hans D, Binkley N et al (2024) Association of trabecular bone score corrected for tissue thickness with glucose metabolism in acromegaly. Front Endocrinol (Lausanne) 15:1448566","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1639_CR158","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/jc.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: A 3-Year prospective study. J Clin Endocrinol Metabolism 98(8):3402\u20133410","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"6","key":"1639_CR159","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1530\/EJE-14-0097","volume":"170","author":"G Mazziotti","year":"2014","unstructured":"Mazziotti G, Mormando M, Cristiano A, Bianchi A, Porcelli T, Giampietro A et al (2014) Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 170(6):893\u2013899","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1639_CR160","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tem.2020.01.011","volume":"31","author":"A Giustina","year":"2020","unstructured":"Giustina A (2020) Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metabolism 31(4):274\u2013275","journal-title":"Trends Endocrinol Metabolism"},{"issue":"2","key":"1639_CR161","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R et al (2015) Bone Turnover, bone mineral Density, and fracture risk in acromegaly: A Meta-Analysis. J Clin Endocrinol Metabolism 100(2):384\u2013394","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"12","key":"1639_CR162","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1210\/jc.2008-0791","volume":"93","author":"G Mazziotti","year":"2008","unstructured":"Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metabolism 93(12):4649\u20134655","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"6","key":"1639_CR163","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3803\/EnM.2023.601","volume":"38","author":"A Giustina","year":"2023","unstructured":"Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metab (Seoul) 38(6):655\u2013666","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"1639_CR164","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000528199","volume":"113","author":"F Bioletto","year":"2023","unstructured":"Bioletto F, Barale M, Prencipe N, Berton AM, Parasiliti-Caprino M, Gasco V et al (2023) Trabecular bone score as an index of bone fragility in patients with acromegaly: A systematic review and Meta-Analysis. Neuroendocrinology 113(4):395\u2013405","journal-title":"Neuroendocrinology"},{"issue":"7","key":"1639_CR165","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"Frara S, Melin Uygur M, di Filippo L, Doga M, Losa M, Santoro S et al (2022) High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J Clin Endocrinol Metab 107(7):e2843\u2013e50","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR166","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","volume":"25","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio MR et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25(6):831\u2013841","journal-title":"Pituitary"},{"issue":"4","key":"1639_CR167","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/EJE-20-0415","volume":"183","author":"ICM Pelsma","year":"2020","unstructured":"Pelsma ICM, Biermasz NR, Pereira AM, van Furth WR, Appelman-Dijkstra NM, Kloppenburg M et al (2020) Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. Eur J Endocrinol 183(4):427\u2013437","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1639_CR168","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1210\/jc.2013-2695","volume":"98","author":"KM Claessen","year":"2013","unstructured":"Claessen KM, Kroon HM, Pereira AM, Appelman-Dijkstra NM, Verstegen MJ, Kloppenburg M et al (2013) Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 98(12):4808\u20134815","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1639_CR169","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11102-016-0758-6","volume":"20","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Maffezzoni F, Frara S, Giustina A (2017) Acromegalic osteopathy. Pituitary 20(1):63\u201369","journal-title":"Pituitary"},{"key":"1639_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American association of clinical Endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal Osteoporosis\u20142020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"issue":"4","key":"1639_CR171","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O, Abrahamsen B, Al-Daghri N, Burlet N et al (2024) Evidence-Based guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20(4):241\u2013251","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1639_CR172","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1639_CR173","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.12262","volume":"80","author":"J Brzana","year":"2014","unstructured":"Brzana J, Yedinak CG, Hameed N, Fleseriu M (2014) FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf) 80(4):614\u2013616","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1639_CR174","doi-asserted-by":"crossref","unstructured":"Mazziotti G, Battista C, Maffezzoni F, Chiloiro S, Ferrante E, Prencipe N et al (2020) Treatment of acromegalic osteopathy in Real-life clinical practice: the BAAC (Bone active drugs in Acromegaly) study. J Clin Endocrinol Metab 105(9):e3285\u2013e3292","DOI":"10.1210\/clinem\/dgaa363"},{"key":"1639_CR175","doi-asserted-by":"crossref","unstructured":"Chiloiro S, Giampietro A, Frara S, Bima C, Donfrancesco F, Fleseriu CM et al (2020) Effects of Pegvisomant and Pasireotide LAR on vertebral fractures in acromegaly resistant to First-generation SRLs. J Clin Endocrinol Metab 105(3):e100\u2013e107","DOI":"10.1210\/clinem\/dgz054"},{"issue":"6","key":"1639_CR176","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40618-023-02281-3","volume":"47","author":"E Vitali","year":"2024","unstructured":"Vitali E, Grasso A, Schiavone ML, Trivellin G, Sobacchi C, Mione M et al (2024) The direct impact of Pegvisomant on osteoblast functions and bone development. J Endocrinol Invest 47(6):1385\u20131394","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1639_CR177","doi-asserted-by":"publisher","first-page":"bvae079","DOI":"10.1210\/jendso\/bvae079","volume":"8","author":"AP Kuker","year":"2024","unstructured":"Kuker AP, Agarwal S, Shane E, Bicca J, Geer EB, Cremers S et al (2024) Long-term Pegvisomant therapy of acromegaly: effects on bone Density, turnover and microstructure using HRpQCT. J Endocr Soc 8(6):bvae079","journal-title":"J Endocr Soc"},{"issue":"6","key":"1639_CR178","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11102-025-01573-6","volume":"28","author":"S Chiloiro","year":"2025","unstructured":"Chiloiro S, Palumbo C, Giampietro A, De Marinis L, Bianchi A, Giustina A et al (2025) Acromegaly treatment and bone: a bidirectional relationship. Pituitary 28(6):124","journal-title":"Pituitary"},{"issue":"3","key":"1639_CR179","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11102-024-01398-9","volume":"27","author":"S Chiloiro","year":"2024","unstructured":"Chiloiro S, Giampietro A, Infante A, Mattogno PP, Lauretti L, Olivi A et al (2024) Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience. Pituitary 27(3):303\u2013309","journal-title":"Pituitary"},{"issue":"3","key":"1639_CR180","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","volume":"21","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, Mazziotti G, Giampietro A, Bianchi A, Frara S, Mormando M et al (2018) Effects of Pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21(3):302\u2013308","journal-title":"Pituitary"},{"key":"1639_CR181","first-page":"89","volume":"6","author":"J Halupczok-\u017by\u0142a","year":"2015","unstructured":"Halupczok-\u017by\u0142a J, Jawiarczyk-Przyby\u0142owska A, Bolanowski M (2015) Patients with active acromegaly are at high risk of 25(OH)D deficiency. Front Endocrinol (Lausanne) 6:89","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1639_CR182","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12020-015-0789-1","volume":"52","author":"AE Altinova","year":"2016","unstructured":"Altinova AE, Ozkan C, Akturk M, Gulbahar O, Yalcin M, Cakir N et al (2016) Vitamin D-binding protein and free vitamin D concentrations in acromegaly. Endocrine 52(2):374\u2013379","journal-title":"Endocrine"},{"issue":"4","key":"1639_CR183","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11154-021-09693-7","volume":"22","author":"JP Bilezikian","year":"2021","unstructured":"Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M et al (2021) Vitamin D: Dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22(4):1201\u20131218","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"1639_CR184","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1210\/endrev\/bnae030","volume":"46","author":"R Basu","year":"2025","unstructured":"Basu R, Boguszewski CL, Kopchick JJ (2025) Growth hormone action as a target in cancer: Significance, Mechanisms, and possible therapies. Endocr Rev 46(2):224\u2013280","journal-title":"Endocr Rev"},{"issue":"4","key":"1639_CR185","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-16-0178","volume":"175","author":"CL Boguszewski","year":"2016","unstructured":"Boguszewski CL, Ayuk J, MANAGEMENT OF ENDOCRINE, DISEASE (2016) Acromegaly and cancer: an old debate revisited. Eur J Endocrinol 175(4):R147\u2013R156","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1639_CR186","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/ERC-16-0553","volume":"24","author":"M Terzolo","year":"2017","unstructured":"Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L et al (2017) Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr Relat Cancer 24(9):495\u2013504","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1639_CR187","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1210\/jc.2017-02457","volume":"103","author":"J Dal","year":"2018","unstructured":"Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C et al (2018) Cancer incidence in patients with acromegaly: A cohort study and Meta-Analysis of the literature. J Clin Endocrinol Metab 103(6):2182\u20132188","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1639_CR188","doi-asserted-by":"publisher","first-page":"e0285335","DOI":"10.1371\/journal.pone.0285335","volume":"18","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Xiao P, Wang Y, Fang C, Li Y (2023) Risk of cancer in acromegaly patients: an updated meta-analysis and systematic review. PLoS ONE 18(11):e0285335","journal-title":"PLoS ONE"},{"issue":"10","key":"1639_CR189","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1210\/jc.2015-2372","volume":"100","author":"D Petroff","year":"2015","unstructured":"Petroff D, T\u00f6njes A, Grussendorf M, Droste M, Dimopoulou C, Stalla G et al (2015) The incidence of cancer among acromegaly patients: results from the German acromegaly registry. J Clin Endocrinol Metab 100(10):3894\u20133902","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR190","first-page":"395","volume":"13","author":"D Baris","year":"2002","unstructured":"Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A et al (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13(5):395\u2013400","journal-title":"Cancer Causes Control"},{"issue":"3","key":"1639_CR191","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/ejendo\/lvaf029","volume":"192","author":"YS Kim","year":"2025","unstructured":"Kim YS, Yun JS, Kim H, Jeun SS, Kim B, Lee SW et al (2025) Acromegaly and the risk of cancer: a nationwide population-based cohort study in Korea. Eur J Endocrinol 192(3):220\u2013227","journal-title":"Eur J Endocrinol"},{"key":"1639_CR192","doi-asserted-by":"crossref","unstructured":"Freda PU, Bruce JN, Jin Z, Kostadinov J, Khandji AG, Cremers S et al (2024) Prospective, longitudinal study of cancer predictors and rates in a new York City cohort of 598 patients with acromegaly. J Clin Endocrinol Metab 110(5):1247\u20131257","DOI":"10.1210\/clinem\/dgae469"},{"issue":"1","key":"1639_CR193","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-20-0281","volume":"183","author":"CL Boguszewski","year":"2020","unstructured":"Boguszewski CL (2020) Acromegaly: \u2018You must know it to think of it\u2019. Eur J Endocrinol 183(1):C1\u2013c4","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1639_CR194","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523\u2013531","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1639_CR195","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ecl.2022.04.004","volume":"51","author":"EC Coopmans","year":"2022","unstructured":"Coopmans EC, Andela CD, Claessen K, Biermasz NR (2022) Evaluating the impact of acromegaly on quality of life. Endocrinol Metab Clin North Am 51(4):709\u2013725","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"1639_CR196","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EJE-17-0041","volume":"177","author":"SM Webb","year":"2017","unstructured":"Webb SM, Crespo I, Santos A, Resmini E, Aulinas A, Valassi E (2017) MANAGEMENT OF ENDOCRINE DISEASE: quality of life tools for the management of pituitary disease. Eur J Endocrinol 177(1):R13\u2013r26","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1639_CR197","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11102-016-0761-y","volume":"20","author":"I Crespo","year":"2017","unstructured":"Crespo I, Valassi E, Webb SM (2017) Update on quality of life in patients with acromegaly. Pituitary 20(1):185\u2013188","journal-title":"Pituitary"},{"key":"1639_CR198","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD et al (2021) Disease and Treatment-Related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1639_CR199","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X et al (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without Pegvisomant. J Clin Endocrinol Metab 93(10):3853\u20133859","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1639_CR200","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","volume":"107","author":"M van der Meulen","year":"2022","unstructured":"van der Meulen M, Zamanipoor Najafabadi AH, Broersen LHA, Schoones JW, Pereira AM, van Furth WR et al (2022) State of the Art of Patient-reported outcomes in acromegaly or GH deficiency: A systematic review and Meta-analysis. J Clin Endocrinol Metab 107(5):1225\u20131238","journal-title":"J Clin Endocrinol Metab"},{"key":"1639_CR201","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fendo.2017.00040","volume":"8","author":"VJ Geraedts","year":"2017","unstructured":"Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C et al (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne) 8:40","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1639_CR202","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/17446651.2024.2363540","volume":"19","author":"M Fleseriu","year":"2024","unstructured":"Fleseriu M, Nachtigall LB, Samson SL, Melmed S (2024) Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use. Expert Rev Endocrinol Metab 19(4):367\u2013375","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"1639_CR203","doi-asserted-by":"publisher","first-page":"101906","DOI":"10.1016\/j.beem.2024.101906","volume":"38","author":"LE Wildemberg","year":"2024","unstructured":"Wildemberg LE, Fialho C, Gadelha MR (2024) Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist Paltusotine. Best Pract Res Clin Endocrinol Metab 38(4):101906","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR204","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D et al (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23(2):140\u2013148","journal-title":"Pituitary"},{"issue":"5","key":"1639_CR205","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","volume":"22","author":"A Giustina","year":"2019","unstructured":"Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C et al (2019) Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT\u00ae validation study. Pituitary 22(5):476\u2013487","journal-title":"Pituitary"},{"issue":"2","key":"1639_CR206","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","volume":"106","author":"LHA Broersen","year":"2021","unstructured":"Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR (2021) Improvement in symptoms and Health-Related quality of life in acromegaly patients: A systematic review and Meta-Analysis. J Clin Endocrinol Metab 106(2):577\u2013587","journal-title":"J Clin Endocrinol Metab"},{"key":"1639_CR207","doi-asserted-by":"crossref","unstructured":"Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C (2015) Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life. Front Endocrinol 5:2014","DOI":"10.3389\/fendo.2014.00229"},{"issue":"1","key":"1639_CR208","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000375450","volume":"103","author":"KM Claessen","year":"2016","unstructured":"Claessen KM, Mazziotti G, Biermasz NR, Giustina A (2016) Bone and joint disorders in acromegaly. Neuroendocrinology 103(1):86\u201395","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"1639_CR209","first-page":"S41","volume":"155","author":"A Barkan","year":"1997","unstructured":"Barkan A (1997) Acromegalic arthropathy and sleep apnea. J Endocrinol 155(Suppl 1):S41\u2013S44 discussion S5","journal-title":"J Endocrinol"},{"issue":"6","key":"1639_CR210","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-16-1073","volume":"176","author":"K Claessen","year":"2017","unstructured":"Claessen K, Canete AN, de Bruin PW, Pereira AM, Kloppenburg M, Kroon HM et al (2017) Acromegalic arthropathy in various stages of the disease: an MRI study. Eur J Endocrinol 176(6):779\u2013790","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1639_CR211","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s11102-024-01465-1","volume":"27","author":"ICM Pelsma","year":"2024","unstructured":"Pelsma ICM, Kroon HM, Andela CD, van der Linden EMJ, Kloppenburg M, Biermasz NR et al (2024) Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management. Pituitary 27(6):824\u2013836","journal-title":"Pituitary"},{"issue":"2","key":"1639_CR212","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1530\/EJE-12-0147","volume":"167","author":"KM Claessen","year":"2012","unstructured":"Claessen KM, Ramautar SR, Pereira AM, Smit JW, Roelfsema F, Romijn JA et al (2012) Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 167(2):235\u2013244","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1639_CR213","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11102-019-00966-8","volume":"22","author":"LM Fatti","year":"2019","unstructured":"Fatti LM, Cangiano B, Vitale G, Persani L, Mantovani G, Sala E et al (2019) Arthropathy in acromegaly: a questionnaire-based Estimation of motor disability and its relation with quality of life and work productivity. Pituitary 22(5):552\u2013560","journal-title":"Pituitary"},{"issue":"6","key":"1639_CR214","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1210\/jcem.83.6.4865","volume":"83","author":"A Colao","year":"1998","unstructured":"Colao A, Marzullo P, Vallone G, Marin\u00f2 V, Annecchino M, Ferone D et al (1998) Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metabolism 83(6):2121\u20132125","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1639_CR215","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","volume":"77","author":"B Cangiano","year":"2022","unstructured":"Cangiano B, Giusti E, Premoli C, Soranna D, Vitale G, Grottoli S et al (2022) Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine 77(3):510\u2013518","journal-title":"Endocrine"},{"issue":"4","key":"1639_CR216","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-16-0242","volume":"175","author":"S Fujio","year":"2016","unstructured":"Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H et al (2016) Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol 175(4):325\u2013333","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1639_CR217","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11102-023-01370-z","volume":"27","author":"H Bostan","year":"2024","unstructured":"Bostan H, Kizilgul M, Calapkulu M, Kalkisim HK, Topcu FBG, Gul U et al (2024) The prevalence and associated risk factors of detectable renal morphological abnormalities in acromegaly. Pituitary 27(1):44\u201351","journal-title":"Pituitary"},{"issue":"4","key":"1639_CR218","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.kint.2023.06.037","volume":"104","author":"S Hong","year":"2023","unstructured":"Hong S, Kim KS, Han K, Park CY (2023) A cohort study found a high risk of end-stage kidney disease associated with acromegaly. Kidney Int 104(4):820\u2013827","journal-title":"Kidney Int"},{"issue":"12","key":"1639_CR219","first-page":"3487","volume":"106","author":"D Esposito","year":"2021","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2021) Incidence of benign and malignant tumors in patients with acromegaly is increased: A nationwide Population-based study. J Clin Endocrinol Metab 106(12):3487\u20133496","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1639_CR220","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1530\/EJE-10-0007","volume":"162","author":"RS Auriemma","year":"2010","unstructured":"Auriemma RS, Galdiero M, De Martino MC, De Leo M, Grasso LF, Vitale P et al (2010) The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol 162(6):1035\u20131042","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1639_CR221","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1210\/jc.2011-3188","volume":"97","author":"P Kamenick\u00fd","year":"2012","unstructured":"Kamenick\u00fd P, Blanchard A, Gauci C, Salenave S, Letierce A, Lomb\u00e8s M et al (2012) Pathophysiology of renal calcium handling in acromegaly: what Lies behind hypercalciuria? J Clin Endocrinol Metab 97(6):2124\u20132133","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1639_CR222","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ejendo\/lvad105","volume":"189","author":"P Wolf","year":"2023","unstructured":"Wolf P, Bouazizi K, Kachenoura N, Piedvache C, Gallo A, Salenave S et al (2023) Increase in intracellular and extracellular myocardial mass in patients with acromegaly: a cardiac magnetic resonance imaging study. Eur J Endocrinol 189(2):199\u2013207","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1639_CR223","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12020-018-1745-7","volume":"63","author":"W He","year":"2019","unstructured":"He W, Yan L, Wang M, Li Q, He M, Ma Z et al (2019) Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases. Endocrine 63(1):27\u201335","journal-title":"Endocrine"},{"issue":"3","key":"1639_CR224","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/1793-5482.145354","volume":"11","author":"D Banerji","year":"2016","unstructured":"Banerji D, Das NK, Sharma S, Jindal Y, Jain VK, Behari S (2016) Surgical management of acromegaly: long term functional outcome analysis and assessment of recurrent\/residual disease. Asian J Neurosurg 11(3):261\u2013267","journal-title":"Asian J Neurosurg"},{"issue":"10","key":"1639_CR225","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1507\/endocrj.EJ18-0108","volume":"65","author":"M Nezu","year":"2018","unstructured":"Nezu M, Kudo M, Morimoto R, Ono Y, Omata K, Tezuka Y et al (2018) Effects of surgical treatment for acromegaly on knee MRI structural features. Endocr J 65(10):991\u2013999","journal-title":"Endocr J"},{"issue":"11","key":"1639_CR226","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1007\/s00701-021-04846-8","volume":"163","author":"S Berkmann","year":"2021","unstructured":"Berkmann S, Brun J, Schuetz P, Christ E, Mariani L, Mueller B (2021) Prevalence and outcome of comorbidities associated with acromegaly. Acta Neurochir (Wien) 163(11):3171\u20133180","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"1639_CR227","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11102-015-0642-9","volume":"18","author":"Y Sasagawa","year":"2015","unstructured":"Sasagawa Y, Tachibana O, Doai M, Tonami H, Iizuka H (2015) Median nerve conduction studies and wrist magnetic resonance imaging in acromegalic patients with carpal tunnel syndrome. Pituitary 18(5):695\u2013700","journal-title":"Pituitary"},{"issue":"5","key":"1639_CR228","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11102-015-0643-8","volume":"18","author":"C Yedinak","year":"2015","unstructured":"Yedinak C, Hameed N, Gassner M, Brzana J, McCartney S, Fleseriu M (2015) Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. Pituitary 18(5):701\u2013709","journal-title":"Pituitary"},{"issue":"3","key":"1639_CR229","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EJE-13-0166","volume":"169","author":"F Bogazzi","year":"2013","unstructured":"Bogazzi F, Colao A, Rossi G, Lombardi M, Urbani C, Sardella C et al (2013) Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol 169(3):367\u2013376","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1639_CR230","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2005-1704","volume":"91","author":"CL Ronchi","year":"2006","unstructured":"Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A et al (2006) Comparison between Six-Year therapy with Long-Acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metabolism 91(1):121\u2013128","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1639_CR231","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/jrms.JRMS_955_18","volume":"24","author":"M Heidarpour","year":"2019","unstructured":"Heidarpour M, Shafie D, Aminorroaya A, Sarrafzadegan N, Farajzadegan Z, Nouri R et al (2019) Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. J Res Med Sci 24:29","journal-title":"J Res Med Sci"},{"issue":"8","key":"1639_CR232","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1210\/jc.2009-2570","volume":"95","author":"C Berg","year":"2010","unstructured":"Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M et al (2010) Cardiovascular risk factors in patients with uncontrolled and Long-Term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metabolism 95(8):3648\u20133656","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"6","key":"1639_CR233","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"Giustina A, Arnaldi G, Bogazzi F, Cannav\u00f2 S, Colao A, De Marinis L et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6):577\u2013589","journal-title":"J Endocrinol Invest"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01639-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:02:18Z","timestamp":1782414138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01639-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":233,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01639-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G. has occasionally consulted for Amolyt, Abiogen, Alexion, Crinetics, Ipsen, Pfizer and Recordati Rare Diseases, and received research grants to the Istitution by Recordati Rare Diseases. L.d.F. received a research grant to their institution from Abiogen Pharma S.p.A. and his research activities are partly supported by Glucocorticoid induced Osteoporosis Skeletal (GIOSEG). M.F. received grants to their institution from Amryt, Crinetics, Ionis and Recordati Rare Diseases, received occasional consulting fees or has served as occasional Advisory Board Member for Amryt, Crinetics, Camurus, Ipsen, and Recordati Rare Diseases. S.P. has been a speaker at workshops and\/or advisory board member for HRA Pharma, Ipsen, Lilly, Novo Nordisk, Pfizer, and Recordati Rare Diseases. S.L.S. is principal investigator for Chiasma (Chiesi) and Pasireotide (Novartis, now Recordati Rare Diseases). C.L.B. has received speaking fees from Ipsen, consulting fees from Ipsen, Recordati Rare Diseases and Novo Nordisk, and is a principal investigator of clinical trials of Crinetics. A.J.v.d.L. has received consulting and speaking fees from Amolyt Pharma, Pfizer. M.G. has received speakers honoraria from Ipsen and Pfizer. K.S. has received honoraria for consulting, speaking and scientific projects from the following companies: Pfizer, Recordati Rare Diseases, Camurus, Crinetics, Novo Nordisk, Ascendis. D.F. received fees for lecture and advisory boards from Novartis, Camurus, Recordati Rare Diseases. M.R.G. has received speaker fees from Recordati Rare Diseases, Ipsen and Novo Nordisk, is member of the advisory board of Recordati Rare Diseases, Ipsen, Novo Nordisk and Crinetics, is principal investigator in clinical trials from Recordati Rare Diseases and Crinetics. A.G.I. occasionally consults for Crinetics, Camurus and Xeris, has received research grants to their institution from Recordati Rare Diseases, Xeris, Chiesi. C.J.S. is an advisory board member or recipient of speaker\u2019s fees from NovoNordisk, Amolyt, Pfizer, Crinetics, Sandoz-Hexal, Recordati Rare Diseases, Debiopharm and ConsilientHealth. P.K. participated in clinical trials of Carmus and Recordati Rare Diseases. . P.M. has been a principal investigator in clinical trials of Ipsen, Pfizer, Camurus, received consultation fee and research support from Pfizer, Recordati Rare Diseases. N.K. has been a speaker for Pfizer, Ipsen, Recordati Rare Diseases, investigator for Pfizer, Ipsen, scientific advisory board for Pfizer, Ipsen, Recordati Rare Diseases. S.C. has received lecture and advisory fees and grants from Ipsen, Recordati Rare Diseases. A.L. has received lecture fees from Ipsen and served as consultant for NovoNordisk. Y.G. participated in clinical trials of Crinetics, Cortendo, Debiopharm and Ascendis. E.V. is on the advisory board for Recordati Rare Diseases, HRA pharma, received speaker fees from Recordati Rare Diseases, HRA Pharma, Ipsen. S.F. has received consultancy and speaker fees from Ipsen and Pfizer, consultancy fee from Novartis, is an advisory board member for Recordati Rare Diseases and Novo Nordisk, and has received grants to their institution from Abiogen Pharma S.p.A. P.C. has received unrestricted research and educational grants from Ipsen, Recordati Rare Diseases, Advanz and Pfizer, is an investigator (principal or coordinator) for clinical trials funded by Chiasma, Recordati Rare Diseases, Pfizer, Crinetics and Debiopharm, is a member of Advisory Boards from Pfizer, Crinetics, Recordati Rare Diseases and Amolyt, lectures for Ipsen, Recordati Rare Diseases and Pfizer. T.B. is clinical trial investigator for Xeris, Crinetics, Debiopharm, Recordati Rare Diseases, is on advisory boards for Pfizer, Recordati Rare Diseases, Novo-Nordisk, received speaker fees from Pfizer, Recordati Rare Diseases, Novo-Nordisk and received research grants from Pfizer. A.C. is a principal investigator of research studies for Novartis, Ipsen, Pfizer, a consultant for Novartis, Ipsen, Pfizer, received honoraria from Novartis, Ipsen and Pfizer. S.N. has received consulting, research and speaking fees from Novo Nordisk, Crinetics, Recordati Rare Diseases, Pfizer. M.P.-D. received funding for advisory board or lectures given at symposia organized by Recordati Rare Diseases, Pfizer, Novartis and Ipsen. S.M. received a research grant to their institution from Recordati Rare Diseases; is a consultant to Ionis, Camurus, NovoNordisk, Chiesi. A.G. is Editor in Chief of Pituitary. L.D.F, R.P. and A.G.I., are Associate Editors of Pituitary. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}